ADC, Cytokine
Total Trials
2
As Lead Sponsor
0
As Collaborator
Total Enrollment
28
NCT06631079
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors
Phase: Phase 1/2
Role: Collaborator
Start: Oct 7, 2024
Completion: Dec 31, 2028
NCT06631092
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Start: Nov 20, 2024
Loading map...